AI-generated summary
The authors report a randomized controlled trial of bright light therapy versus dim-light control in hospitalized patients with depression over two weeks. Compared with controls, the bright light group showed reductions in fasting blood glucose and cortisol mesor, and the authors suggest a link between these changes that may support a potential mechanism.
- Who or what was studied
- Hospitalized patients with depression
- Limits stated in the abstract
- The abstract does not report the total number of participants or wavelengths, and the authors describe the proposed mechanism only as potential.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Depressed patients with comorbid metabolic disorders have poorer quality of life and prognosis. Pharmacological interventions carries risks of liver and kidney toxicity, which highlights the need for safer non-pharmacological alternatives. Experimental data suggest that light exposure modulates cortisol secretion, thereby influencing metabolic outcomes in depression. We hypothesized that bright light therapy may ameliorate metabolic disturbances by modulating cortisol secretion.
Methods
In this randomized controlled trial, hospitalized patients with depression were assigned to receive either bright light therapy (BLT) or dim-light control condition. The pre-specified primary endpoint was the change in fasting blood glucose (FBG) and cortisol rhythm indices from baseline to post-treatment. Secondary endpoints included changes in other glycolipid parameters, and scores on the Hamilton Depression (HAMD) and Anxiety (HAMA) scales. Treatment effects were evaluated using linear mixed-effects models with baseline adjustment.
Results
After the 2-week intervention, the BLT group showed a significant reduction in fasting blood glucose (95% CI: 0.280 to 0.600; p < 0.001) and cortisol mesor (95% CI: -2.677 to -0.064; p = 0.040) compared to the control group. Within the BLT group, the change in FBG was positively associated with the change in cortisol mesor after adjusting for covariates (β = 0.053, 95% CI: 0.016 to 0.122, p = 0.036).
Conclusions
The findings of this study support a potential mechanism whereby BLT modulates cortisol rhythmicity, which in turn may contribute to improved glycemic control, pointing to its potential therapeutic benefit for addressing metabolic disturbances in depression. CLINICAL
Trial Registration
https://www.chictr.org.cn/bin/project/edit?pid=260569, identifier ChiCTR2500097364.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Depression, Bright light therapy, Randomized controlled trial, Trial registration, Control group, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.